Johnson & Johnson Fined $2.2 Billion: Marketed Risperdal For Off-Label Use
By Marilyn T. McGoldrick, Esq. Posted on Nov 15, 2013 Although only approved by the Food and Drug Administration for certain patients with specific psychiatric disorders, Johnson & Johnson marketed Risperdal for a variety of non-approved, “off label,” uses. This...
DePuy ASR: First Bellwether Trial Postponed For Two Weeks
By Marilyn T. McGoldrick, Esq. Posted on Sep 9, 2013 The first DePuy ASR bellwether trial over Johnson & Johnson DePuy Unit’s hip implants, scheduled to begin today, September 9th in the consolidated federal Multi-District Litigation, has been adjourned for...
Depuy Hip Recipients Prepare For More Trials In Hip Implant Litigation
By Marilyn T. McGoldrick, Esq. Posted on Sep 3, 2013 The first bellwether trial in the federal court Multi-District Litigation over Johnson & Johnson’s DePuy Unit’s metal hip implants is scheduled to begin on Monday, September 9, 2013. The plaintiff...
